epigallocatechin gallate has been researched along with u 0126 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Feghali, K; Grenier, D; Lombardo Bedran, TB; Palomari Spolidorio, DM; Zhao, L | 1 |
2 other study(ies) available for epigallocatechin gallate and u 0126
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Green tea extract and its major constituent, epigallocatechin-3-gallate, induce epithelial beta-defensin secretion and prevent beta-defensin degradation by Porphyromonas gingivalis.
Topics: beta-Defensins; Butadienes; Camellia sinensis; Catechin; Cell Line; Cell Survival; Enzyme Inhibitors; Epithelial Cells; Gingiva; Humans; Imidazoles; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; p38 Mitogen-Activated Protein Kinases; Plant Extracts; Porphyromonas gingivalis; Proteolysis; Pyridines; Up-Regulation | 2014 |